|
Published by: Visiongain
Published: Sep. 18, 2009 - 152 Pages
Table of Contents
- 1. Executive Summary
- 1.1 Aims of this Report
- 1.2 Chapter Breakdown
- 2. Neurodegenerative Diseases: An Introduction
- 2.1 What Are Neurodegenerative Diseases?
- 2.2 Prevalence and Economic Impact
- 2.3 Types of Neurodegenerative Diseases
- 2.3.1 Parkinson's Disease
- 2.3.2 Alzheimer's Disease
- 2.3.3 Multiple Sclerosis
- 2.3.4 Huntington's Disease
- 2.3.5 Amyotrophic Lateral Sclerosis
- 2.3.6 Neuropathies
- 2.3.7 Prion Diseases
- 3. Neurodegenerative Diseases, Global Market 2009-2024
- 3.1 Analysis of the Current Market
- 3.2 Neurodegenerative Diseases, Forecast 2009-2024
- 3.3 Symptomatic Treatment
- 3.4 Multiple Sclerosis at the Forefront of the Market
- 3.5 Future Directions
- 4. Parkinson's Disease
- 4.1 Prevalence and Economic Impact
- 4.2 Current Treatment Options
- 4.3 Parkinson's Disease Market Forecast 2009-2024
- 4.4 Sifrol Forecast 2009-2024
- 4.4.1 Patent Expiries
- 4.5 Stalevo Forecast 2009-2024
- 4.5.1 Patent Expiries and Generic Challenges
- 4.5.2 The FIRST STEP trial
- 4.6 ReQuip Forecast 2009-2024
- 4.6.1 Patents and Lifecycle Management
- 4.7 Concluding Remarks
- 5. Alzheimer's Disease
- 5.1 Prevalence and Economic Impact
- 5.2 Treatment Options
- 5.3 Analysis of the Current Market
- 5.4 Alzheimer's Disease Market Forecast 2009-2024
- 5.5 Aricept Forecast 2009-2024
- 5.5.1 Patents
- 5.6 Namenda Forecast 2009-2024
- 5.6.1 Patents and Generic Challenges
- 5.7 Exelon Forecast 2009-2024
- 5.7.1 Patent Expiries
- 5.8 Reminyl Forecast 2009-2024
- 5.8.1 Generic Challenges
- 5.9 Future Directions and Concluding Remarks
- 6. Multiple Sclerosis
- 6.1 Economic and Social Impact
- 6.1.1 Prevalence
- 6.2 Treatment Options
- 6.2.1 Treatment for Relapses
- 6.2.2 Treatment for Symptoms
- 6.2.3 Disease-Modifying Medicines
- 6.3 Analysis of the Current Market
- 6.4 Multiple Sclerosis Market Forecast 2009-2024
- 6.5 Avonex Forecast 2009-2024
- 6.5.1 Markets and Patent Expiries
- 6.5.2 Strong Competition Will Erode Market Share
- 6.6 Copaxone Forecast 2009-2024
- 6.6.1 A Unique Therapy - For Now
- 6.6.2 Forthcoming Patent Expiries
- 6.7 Rebif Forecast 2009-2024
- 6.7.1 New Delivery Mechanism to Improve Sales
- 6.7.2 Efficacy Studies
- 6.8 Betaferon Forecast 2009-2024
- 6.8.1 Patent Expiries
- 6.8.2 Strong Competition
- 6.9 Future Directions
- 6.9.1 The Re-Launch of Tysabri
- 7. Amyotrophic Lateral Sclerosis
- 7.1 Possible Causes of ALS
- 7.2 Prevalence
- 7.3 Treatment Options
- 7.4 Analysis of the Current Market
- 7.5 Amyotrophic Lateral Sclerosis Market Forecast 2009-2024
- 7.6 Rilutek Forecast 2009-2024
- 7.6.1 New Indications
- 7.6.2 Patents
- 7.7 Future Directions
- 7.7.1 Insmed's Iplex
- 8. Neuropathies
- 8.1 Treating the Underlying Cause
- 8.2 Surgery and Physical Therapy
- 8.3 Pharmacological Treatments
- 8.3.1 Aldose Reductase Inhibitors
- 8.3.2 Antidepressants
- 8.3.3 Analgesics
- 8.3.4 Anticonvulsants
- 8.4 Analysis of the Current Market
- 8.4.1 Economic and Social Impact
- 8.4.2 Increasing Prevalence and Treatment Strategies
- 8.5 Neuropathies Market Forecast 2009-2024
- 8.6 Kinedak Forecast 2009-2024
- 8.6.1 Adverse Effects and Safety Warnings
- 8.6.2 Direct Competition in the Pipeline
- 8.7 Future Directions
- 9. Huntington's Disease
- 9.1 Prevalence and Economic Impact
- 9.2 Treatment Options
- 9.2.1 Monoamine-Depleting Agents
- 9.2.2 Benzodiazepines
- 9.2.3 Dopamine Antagonists
- 9.3 Analysis of the Current Market and Future Directions
- 10. Prion Diseases
- 10.1 Creuztfeldt-Jacob Disease
- 10.2 Gerstmann-Straussler-Scheinker Disease
- 10.3 Kuru
- 10.4 Fatal Familial Insomnia
- 10.5 Prevalence
- 10.6 Analysis of the Current Market
- 10.6.1 Increasing Prevalence Could Alter the Market
- 11. Geographical Breakdown of the Market
- 11.1 USA
- 11.2 Europe
- 11.3 Emerging Markets
- 11.3.1 China versus India
- 11.3.2 Brazil
- 11.4 Concluding Remarks
- 12. Future Directions
- 12.1 Stem Cell Therapy for Neurodegenerative Diseases
- 12.2 Cybrids: "Disease in a Dish" Models
- 12.3 Gene Therapy: Promising Results
- 12.4 Hopes for Alzheimer's Treatment
- 12.4.1 Monoclonal Antibody Bapineuzumab (AAB-001)
- 12.4.2 Monoclonal Antibody Solanezumab
- 12.5 The MS Pipeline
- 12.5.1 Monoclonal Antibodies for the Treatment of MS
- 12.5.2 Managing Immune Activity
- 12.5.3 Statins: A Further Role?
- 12.5.4 Concluding Remarks on the MS Pipeline
- 12.6 Huntington's Disease: Future Developments
- 12.6.1 Dimebon
- 12.6.2 Cystamine
- 12.6.3 HDAC Inhibitors
- 12.6.4 RNAi as a Potential Treatment
- 12.6.5 The Case for Brain-Derived Neurotrophic Factor (BDNF)
- 12.6.6 What About Stem Cells and Gene Therapy?
- 12.7 ALS: The Pipeline
- 12.7.1 Knopp Neurosciences' KNS-760704
- 12.7.2 CytRx Corporation's Arimoclomol
- 13. Drivers and Restraints
- 13.1 Drivers in the Market
- 13.1.1 The Ageing Population and Increasing Prevalence
- 13.1.2 The MS Market: Oral Products May Expand Revenues
- 13.1.3 Advances in Research
- 13.1.4 Chronic Diseases: Long-Term Repeat Sales
- 13.1.5 Unmet Needs in the Patient Population
- 13.2 Restraints in the Market
- 13.2.1 High Product Competition
- 13.2.2 The High Cost of Treatment
- 13.2.3 The MS Market: Patient Compliance
- 13.2.4 Patent Expiries and Generic Competition
- 13.3 Concluding Remarks
- 14. Expert Opinions
- 14.1 Interview with Dr Johan Luthman
- 14.1.1 On Understanding the Disease and its Treatments
- 14.1.2 On Unmet Needs for Treatments
- 14.1.3 On Current Treatment Options
- 14.1.4 On Future Treatment Possibilities
- 14.1.5 On Stem Cell Media Coverage
- 14.1.6 On the Therapeutic and Curative Potential of Stem Cells for Neurological Diseases
- 14.1.7 On the Treatment of Neurological Diseases
- 14.1.8 On the Time Frame for Marketable Stem Cell Treatment Options
- 14.2 Interview with Dr Allan Tobin (CHDI Foundation)
- 14.2.1 On the Possibility of a Cure
- 14.2.2 On the Pipeline for Huntington's Disease
- 14.2.3 On the Advantages and Disadvantages of Studying Huntington's Disease
- 14.2.4 On the Market Value of a Treatment for Huntington's Disease
- 14.3 Interview with Professor Peter Jenner (Proximagen Neurosciences and King’s College, University of London)
- 14.3.1 On the Challenges in the Treatment of Parkinson’s Disease
- 14.3.2 On Promising Therapeutics
- 14.3.3 On the Possibility of a Cure
- 14.3.4 On Stem Cells in the Treatment of Parkinson’s Disease
- 14.3.5 On Important Areas of Research
- 15. Conclusions
- 15.1 Multiple Sclerosis Treatments Lead the Market Area
- 15.2 Chronic Conditions and Treatment Options
- 15.3 Comments on the Global Market
- 15.4 Potential in the Pipeline
- 15.5 Geographical Opportunities
- List of Tables
- Table 2.1 Types of Neurodegenerative Diseases
- Table 3.1 Neurodegenerative Diseases Market: World Sales ($m), 2008-2014, 2019 and 2024
- Table 4.1 Parkinson's Disease Symptoms
- Table 4.2 Key Anti-Parkinson Drugs, World Sales ($m) and Market Share (%), 2008
- Table 4.3 Anti-Parkinson's Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
- Table 5.1 FDA Approved Alzheimer's Therapeutics, 2009
- Table 5.2 Key Anti-Alzheimer's Drugs, World Sales ($m) and Market Share (%), 2008
- Table 5.3 Anti-Alzheimer's Disease Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
- Table 6.1 Multiple Sclerosis: Possible Risk Factors
- Table 6.2 Multiple Sclerosis Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
- Table 6.3 Leading MS Drugs, World Market Share (%), 2008, 2014, 2019 and 2024
- Table 7.1 Factors Associated With the Onset of ALS
- Table 7.2 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
- Table 8.1 Apparent Causes for Neuropathy
- Table 8.2 Top-Selling Local Anaesthetics ($m), 2008
- Table 8.3 Key Therapeutics Indicated for Neuropathies, 2009
- Table 8.4 Neuropathies Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
- Table 9.1 Treatment Options for Huntington's Disease, 2009
- Table 10.1 Number of Suspected CJD and GSS Cases in the UK, 1998-2008
- Table 11.1 The Neurodegenerative Market by Country, Sales ($m), CAGR (%) and Market Share (%), 2008-2014, 2019 and 2024
- Table 12.1 Number of Pipeline Products by Phase and Disease, 2009
- Table 12.2 Key Products in the MS Pipeline, 2009
- Table 13.1 SWOT Analysis for Neurodegenerative Diseases, 2009
- List of Figures
- Figure 3.1 The Neurodegenerative Market World Sales ($m), 2008
- Figure 3.2 Neurodegenerative Diseases Market World Sales ($m), 2008-2024
- Figure 3.3 Neurodegenerative Market by Therapeutic Area, World Sales ($m), 2009, 2014 2019, 2024
- Figure 4.1 Anti-Parkinson's Therapeutics World Sales ($m), 2008-2024
- Figure 4.2 Anti-Parkinson's Drugs, World Market Share (%), 2008
- Figure 4.3 Sifrol World Sales ($m), 2008-2024
- Figure 4.4 Stalevo World Sales ($m), 2008-2024
- Figure 4.5 ReQuip World Sales ($m), 2008-2024
- Figure 5.1 Key Anti-Alzheimer's Drugs, World Market Share (%), 2008
- Figure 5.2 Anti-Alzheimer's Disease Therapeutics World Sales ($m), 2008-2024
- Figure 5.3 Anti-Alzheimer's Disease Therapeutics World Sales ($m), 2009, 2014, 2019 and 2024
- Figure 5.4 Aricept World Sales ($m), 2008-2024
- Figure 5.5 Namenda World Sales ($m), 2008-2024
- Figure 5.6 Exelon World Sales ($m), 2008-2024
- Figure 5.7 Reminyl World Sales ($m), 2008-2024
- Figure 6.1 Multiple Sclerosis Therapeutics World Sales ($m), 2008-2024
- Figure 6.2 Key Multiple Sclerosis Therapeutic Products, World Sales ($m), 2008
- Figure 6.3 Avonex World Sales ($m), 2008-2024
- Figure 6.4 Copaxone World Sales ($m), 2008-2024
- Figure 6.5 Rebif World Sales ($m), 2008-2024
- Figure 6.6 Betaferon World Sales ($m), 2008-2024
- Figure 6.7 Leading MS Drugs, World Market Share (%), 2008
- Figure 6.8 Leading MS Drugs, World Market Share (%), 2024
- Figure 6.9 Leading MS Drugs, World Sales ($m), 2008, 2014, 2019, 2024
- Figure 7.1 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2008-2024
- Figure 7.2 Rilutek World Sales ($m), 2008-2024
- Figure 7.3 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2009, 2014, 2019 and 2024
- Figure 8.1 Neuropathies Therapeutics World Sales ($m), 2008-2024
- Figure 8.2 Neuropathic Pain and General Neuropathic Therapeutics, World Market Share (%), 2008
- Figure 8.3 Neuropathic Pain and General Neuropathic Therapeutics, World Sales ($m), 2009, 2014, 2019 and 2024
- Figure 8.4 Kinedak World Sales ($m), 2008-2024
- Figure 8.5 Kinedak and Other General Neuropathic Products, World Sales ($m), 2008, 2014, 2019 and 2024
- Figure 10.1 Number of Suspected CJD and GSS Cases in the UK, 1998-2008
- Figure 11.1 The Neurodegenerative Market by Country, Sales ($m), 2009, 2014, 2019 and 2024
- Figure 11.2 European Neurodegenerative Market, Sales ($m), 2009, 2014, 2019 and 2024
- Figure 11.3 China, India and Brazil, Sales ($m), 2009, 2014, 2019 and 2024
- Figure 11.4 Geographical Breakdown of the World Market, Sales ($m), 2008
- Figure 11.5 Geographical Breakdown of the World Market, Sales ($m), 2024
- Figure 12.1 Number of Pipeline Products by Phase and Disease, 2009
- Figure 12.2 Number of Products in the Alzheimer's Pipeline by Phase, 2009
- Companies Listed
- Acorda Therapeutics
- Active Biotech
- Aguettant
- AstraZeneca
- Bayer
- Biogen Idec
- BioMS Medical
- Boehringer Ingelheim
- Cobalt
- CHDI Foundation
- CytRx Corporation
- Dainippon Sumitomo
- Dr. Reddy's Laboratories
- Eisai
- Elan
- Eli Lilly
- EMD Serono
- EMEA
- Endo
- Forest
- GlaxoSmithKline
- Hermes
- Insmed
- InterMune
- Johnson & Johnson
- Knopp Neurosciences
- Lundbeck
- Lupin
- Medivation
- Merck & Co
- Merck Serono
- Merck KGaA
- Momenta Pharmaceuticals
- Mylan
- Natco
- Neuren
- Novartis
- Ono Pharmaceuticals
- Orchid
- Orion Corporation
- Pfizer
- Proximagen Neurosciences
- ReceptoPharm
- Roche
- Roxane
- Sanofi-Aventis
- Sun Pharmaceuticals
- Takeda
- Teva
- The Alzheimer's Association
- The European Medicines Agency
- The Human Fertilisation and Embryology Authority
- The National Academy of Sciences
- The World Health Organisation (WHO)
- Upsher-Smith
- US Food and Drug Administration (FDA)
- Watson Pharmaceuticals
- Wockhardt
- Wyeth
AbstractThe ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer's disease and Parkinson's disease - will lead to further expansion of the neurodegenerative therapies market. Increasing disease prevalence and a robust pipeline make that sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where the most-exciting developments will lie from the present onwards.
This report examines markets for treating the following disorders in particular:
- Parkinson's disease
- Alzheimer's disease
- Multiple sclerosis
- Amyotrophic lateral sclerosis
- Neuropathies.
Also covered are the following neurodegenerative disorders:
- Huntington’s disease
- Prion diseases.
What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market area? Where will the best commercial opportunities lie from 2009 onwards? What are the most-crucial drivers and restraints in this market? This report will provide you with the information that you need to understand current trends and future directions in neurodegenerative disorder therapies. In particular, we discuss prospects for the following products in detail:
- Sifrol
- Stalevo
- Requip
- Aricept
- Namenda
- Exelon
- Reminyl
- Avonex
- Copaxone
- Rebif
- Betaferon
- Rilutek.
In our pipeline analyses we include emerging therapeutics such as stem cells, gene therapy and monoclonal antibodies, among other prominent developments.
Detailed analysis of the neurodegenerative disorders market sector
World Neurodegenerative Diseases Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 63 tables and figures included, as well as three full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Research interviews from our comprehensive survey
This report contains visiongain interviews with the following relevant experts:
1) Dr Johan Luthman, former Global Head of Exploratory Medicine (Neurology, Autoimmune & Inflammatory Diseases), Merck Serono
2) Dr Allan Tobin, Senior Scientific Advisor to the CHDI Foundation
3) Professor Peter Jenner, founder and Chief Science Officer, Proximagen Neurosciences, and Professor in Pharmacology, King's College, University of London.
Why you should buy World Neurodegenerative Diseases Market 2009-2024
In this report you will receive the following benefits in particular:
- You will assess the current market for neurodegenerative disease therapeutics
- You will review the overall neurodegenerative disease therapeutics market, including a global sales forecast for 2009 to 2024
- You will receive sales forecasts for neurodegenerative disorder submarkets from 2009 to 2024, with detailed discussions
- You will receive sales forecasts for leading products from 2009 to 2024, with detailed discussions of market potential and competition
- You will receive sales forecasts for leading geographical markets from 2009 to 2024, with informed discussion
- You will examine commercial drivers and restraints in depth
- You will discover the most-exciting pipeline developments in the sector, with informed commentary
- You will discover expert opinions from our original survey of the sector, with prominent contributions from industry and academia.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
